ID   LB33-MELB
AC   CVCL_E934
SY   LB33-MEL.B
DR   Wikidata; Q54902060
RX   PubMed=7875194;
RX   PubMed=28636941;
CC   From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium.
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=28636941).
CC   Derived from site: Metastatic; Small intestine; UBERON=UBERON_0002108.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_E933 ! LB33-MELA
OI   CVCL_ZG34 ! LB33-MELC
OI   CVCL_ZG35 ! LB33-MELD
SX   Female
AG   48Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 19-12-24; Version: 15
//
RX   PubMed=7875194; DOI=10.1002/eji.1830250206;
RA   Lehmann F., Marchand M., Hainaut P., Pouillart P., Sastre-Garau X.,
RA   Ikeda H., Boon T., Coulie P.G.;
RT   "Differences in the antigens recognized by cytolytic T cells on two
RT   successive metastases of a melanoma patient are consistent with immune
RT   selection.";
RL   Eur. J. Immunol. 25:340-347(1995).
//
RX   PubMed=28636941; DOI=10.1016/j.celrep.2017.05.046;
RA   Viceconte N., Dheur M.-S., Majerova E., Pierreux C.E., Baurain J.-F.,
RA   van Baren N., Decottignies A.;
RT   "Highly aggressive metastatic melanoma cells unable to maintain
RT   telomere length.";
RL   Cell Rep. 19:2529-2543(2017).
//